G
Giuseppe Gallo
Publications - 3
Citations - 276
Giuseppe Gallo is an academic researcher. The author has contributed to research in topics: Vaccination & Hematopoietic stem cell transplantation. The author has an hindex of 3, co-authored 3 publications receiving 153 citations.
Papers
More filters
Journal ArticleDOI
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Catherine Cordonnier,Sigrun Einarsdottir,Simone Cesaro,Roberta Di Blasi,Malgorzata Mikulska,Christina Rieger,Hugues de Lavallade,Giuseppe Gallo,Thomas Lehrnbecher,Dan Engelhard,Per Ljungman +10 more
TL;DR: It is recommended to start crucial vaccinations with inactivated vaccines from 3 months after transplant, irrespectively of whether the patient has or has not developed graft-versus-host disease (GvHD) or received immunosuppressants.
Journal ArticleDOI
Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
Malgorzata Mikulska,Simone Cesaro,Hugues de Lavallade,Roberta Di Blasi,Sigrun Einarsdottir,Giuseppe Gallo,Christina Rieger,Dan Engelhard,Thomas Lehrnbecher,Per Ljungman,Catherine Cordonnier +10 more
TL;DR: In this article, the authors present guidelines for patients without transplantations, and address the issue by the haematological group-myeloid and lymphoid-of diseases, with a special consideration for children with acute leukaemia.
Journal ArticleDOI
Venoocclusive disease due to chemotherapy for pediatric acute lymphoblastic leukemia is associated with increased levels of plasminogen-activator inhibitor-1
Margherita Mauro,Graziella Saggiorato,Maria Teresa Sartori,Giuseppe Gallo,Massimiliano De Bortoli,Elisa Bonetti,Ada Zaccaron,Virginia Vitale,Rita Balter,Matteo Chinello,Simone Cesaro +10 more
TL;DR: In all three episodes, the clinical diagnosis of SOS was associated with a significant increase in plasminogen‐activator inhibitor‐1 (PAI‐1) that reduced with patient clinical improvement and warrants study as a diagnostic marker for SOS in ALL.